Evofem Biosciences Balance Sheet Health
Financial Health criteria checks 0/6
Evofem Biosciences has a total shareholder equity of $-61.9M and total debt of $43.3M, which brings its debt-to-equity ratio to -69.9%. Its total assets and total liabilities are $10.6M and $72.5M respectively.
Key information
-69.9%
Debt to equity ratio
US$43.27m
Debt
| Interest coverage ratio | n/a |
| Cash | US$639.00k |
| Equity | -US$61.92m |
| Total liabilities | US$72.47m |
| Total assets | US$10.55m |
Recent financial health updates
Recent updates
Evofem partners with a360 Media to support Phexxi prescription growth
Jul 21Evofem announces peer-reviewed publication on birth control method
Jul 12Female Contraception Post Roe V. Wade - Evofem CEO Saundra Pelletier
Jul 06Evofem announces U.S. patent win for birth control method
Jun 30Evofem: ACA Coverage Of Phexxi Is A Game Changer
Jan 18Financial Position Analysis
Short Term Liabilities: EVFM has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: EVFM has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: EVFM has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: EVFM's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: EVFM's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if EVFM's interest payments on its debt are well covered by EBIT.